SM
SMMT.US Summit Therapeutics PLC
- Market cap
- USD 8.61B
- P/E
- -
- P/B
- 20.03x
- ROE
- -144.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SMMT.US undervalued?
Graham numberThe Graham number of Summit Therapeutics PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Summit Therapeutics PLC fundamental analysis
No fundamental analysis for Summit Therapeutics PLC yet.
Summit Therapeutics PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is i…
Full company profileSummit Therapeutics PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Summit Therapeutics PLC annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.38M | 14.2M | 57.1M | 43.0M | 860K | 1.81M | 705K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.38M | 14.2M | 56.4M | 43.0M | 860K | 1.81M | 705K | -2.05M | -15.0M | -108K | - |
| Operating Income | -24.9M | -25.8M | 5.39M | 15.2M | -98.0M | -86.2M | -72.1M | -610M | -226M | -1.09B | -840M |
| EBITDA | -24.8M | -26.2M | 11.7M | 15.7M | -49.6M | -83.7M | -62.1M | -88.5M | -211M | -1.08B | -818M |
| Net Income | -21.4M | -20.2M | 10.9M | 4.99M | -52.7M | -86.1M | -78.8M | -615M | -221M | -1.08B | -818M |
| EPS | -0.35 | -0.31 | 0.13 | 0.15 | -0.76 | -0.93 | -0.41 | -0.99 | -0.31 | -1.44 | -1.02 |
| Balance Sheet | |||||||||||
| Total Assets | 47.0M | 76.4M | 79.5M | 75.5M | 102M | 113M | 664M | 203M | 436M | 751M | 693M |
| Total Liabilities | 51.3M | 62.4M | 23.7M | 14.3M | 23.0M | 30.1M | 538M | 125M | 46.8M | 92.3M | 128M |
| Shareholders' Equity | -4.37M | 14.0M | 55.8M | 61.1M | 79.5M | 83.3M | 127M | 77.7M | 389M | 659M | 565M |
| Cash & Short-term Investments | 35.1M | 28.5M | 35.2M | 50.0M | 66.4M | 71.8M | 349M | 186M | 412M | 713M | 630M |
| Total Debt | 5.09M | 18.0M | 0.00 | 700K | 465K | 2.78M | 519M | 106M | 7.22M | 20.9M | 20.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.2M | -20.6M | -35.1M | -26.7M | -48.1M | -72.6M | -41.6M | -76.8M | -142M | -323M | -600M |
| Capital Expenditure | 110K | 678K | 164K | 265K | 421K | 306K | 624K | 128K | 139K | 657K | 2.15M |
| Free Cash Flow | 15.1M | -21.3M | -35.3M | -26.9M | -48.5M | -72.9M | -42.2M | -76.9M | -142M | -324M | -602M |
| Ratios | |||||||||||
| ROE | - | -144.2% | 19.5% | 8.2% | -66.3% | -103.4% | -62.2% | -791.5% | -56.9% | -163.9% | -144.9% |
| ROA | -45.5% | -26.4% | 13.7% | 6.6% | -51.4% | -76.0% | -11.9% | -303.0% | -50.8% | -143.7% | -118.1% |
| Net Profit Margin | -899.5% | -142.3% | 19.0% | 11.6% | -6,127.6% | -4,762.1% | -11,174.8% | - | - | - | - |
| Debt to Equity | - | 1.29x | 0.00x | 0.01x | 0.01x | 0.03x | 4.10x | 1.37x | 0.02x | 0.03x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Summit Therapeutics PLC dividends
Summit Therapeutics PLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:1 on Sep 21, 2020.
Who owns Summit Therapeutics PLC
- Insiders 80.68%
- Institutions 17.16%
- Public & others 2.16%
- Shares outstanding 800M
- Free float 154M
Top funds holding SMMT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 5.12M | 0.64% | +37.81% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.90M | 0.49% | +2.69% | Oct 2026 |
| Vanguard Small Cap Index | 3.59M | 0.45% | +34.22% | Sep 2026 |
| T. Rowe Price Health Sciences | 3.35M | 0.42% | +4.95% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 2.34M | 0.29% | +37.39% | Sep 2026 |
| Fidelity Growth Company Fund | 2.05M | 0.26% | -22.71% | Aug 2026 |
| iShares Biotechnology ETF | 1.19M | 0.15% | -0.19% | Oct 2026 |
| Fidelity Select Biotechnology | 1.07M | 0.13% | 0.00% | Aug 2026 |
| abrdn Healthcare Investors | 994K | 0.12% | -6.46% | Oct 2026 |
| iShares Russell Mid-Cap Growth ETF | 782K | 0.10% | -0.07% | Oct 2026 |
| Fidelity Select Health Care | 750K | 0.09% | -6.25% | Aug 2026 |
| Fidelity Extended Market Index | 737K | 0.09% | -3.27% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 681K | 0.09% | +0.20% | Oct 2026 |
| abrdn Life Sciences Investors | 637K | 0.08% | -5.79% | Oct 2026 |
| Fidelity Series Growth Company | 599K | 0.07% | -7.72% | Aug 2026 |
| iShares Russell Mid-Cap ETF | 586K | 0.07% | -0.06% | Oct 2026 |
| International Biotechnology Ord | 556K | 0.07% | -33.50% | Jul 2026 |
| Fidelity Mid Cap Index | 550K | 0.07% | +6.03% | Sep 2026 |
| Candriam Eqs L Biotech C USD Cap | 541K | 0.07% | 0.00% | Apr 2026 |
| Franklin Biotechnology Discv A(acc)USD | 525K | 0.07% | 0.00% | Sep 2026 |
Top institutions holding SMMT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 32.8M | 4.10% | -9.91% | Jun 2026 |
| FMR Inc | 10.0M | 1.26% | -7.46% | Jun 2026 |
| State Street Corp | 9.54M | 1.19% | +35.69% | Jun 2026 |
| BlackRock Inc | 9.53M | 1.19% | -1.29% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.73M | 0.72% | +0.40% | Jun 2026 |
| UBS Group AG | 5.23M | 0.65% | +42.21% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 5.04M | 0.63% | -3.65% | Jun 2026 |
| The Goldman Sachs Group Inc | 4.51M | 0.56% | +1,352.52% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.89M | 0.49% | -52.96% | Jun 2026 |
| Point72 Asset Management, L.P. | 3.70M | 0.46% | +371.55% | Jun 2026 |
| Geode Capital Management, LLC | 3.43M | 0.43% | +3.36% | Jun 2026 |
| Millennium Management LLC | 2.35M | 0.29% | +1,760.32% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.99M | 0.25% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 1.90M | 0.24% | +247.28% | Jun 2026 |
| Aberdeen Group PLC | 1.74M | 0.22% | +2.68% | Sep 2026 |
| Citadel Advisors Llc | 1.73M | 0.22% | +290.66% | Jun 2026 |
| Squarepoint Ops LLC | 1.59M | 0.20% | +159.13% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.45M | 0.18% | -12.15% | Jun 2026 |
| NORGES BANK | 1.38M | 0.17% | +0.62% | Jun 2026 |
| Logos Global Management LP | 1.35M | 0.17% | 0.00% | Jun 2026 |
Summit Therapeutics PLC company profile
- Company name
- Summit Therapeutics PLC
- Ticker
- SMMT.US
- Exchange
- USA Stocks
- Listed since
- Mar 5, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 265
- Fiscal year end
- December
- Address
- 601 Brickell Key Drive, Miami, FL, United States, 33131
- Phone
- 305 203 2034
- Website
- smmttx.com
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Summit Therapeutics PLC management
10- Mr. Robert W. DugganCo-CEO & Executive Chairman · born 1944
- Dr. Mahkam Zanganeh D.D.S., M.B.A.Co-CEO, President & Director · born 1970
- Mr. Manmeet Singh Soni CPACOO, CFO & Director · born 1978
- Prof. Kay Elizabeth Davies DBE, FRS CBECo-Founder, Chairman of Scientific Advisory Board and Scientific Advisor · born 1951
- Mr. Bhaskar AnandChief Accounting Officer & Head of Finance · born 1978
- Mr. Nathan LiaBraatenSenior Director of Investor Relations
- Dr. Elaine Carla Stracker J.D., Ph.D.Chief Legal Officer · born 1961
- Mr. Dave Gancarz CPAChief Business & Strategy Officer
- Dr. Wang Clow Fong ScDChief Biometrics Officer · born 1958
- Dr. Urte Gayko Ph.D.Chief Regulatory, Quality & Pharmacovigilance Officer · born 1971